Austar Lifesciences Limited provided unaudited consolidated earnings guidance for the six months ended 30 June 2020. For the period, the Group is expected to record a profit attributable to the owners of the Company of no less than RMB 12 million for the six months ended 30 June 2020, as compared to the profit attributable to the owners of the Company of approximately RMB 4.2 million for the six months ended 30 June 2019.